BBNX Beta Bionics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1674632 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY43.7%
TTM net income YoY-6.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin58.6%
Operating margin-72.7%
Net margin-65.3%
FCF margin-51.8%
EBITDA margin-70.6%
Returns
ROE-23.9%
ROA-21.5%
ROIC (approx.)-25.4%
Asset turnover0.33x
Leverage & solvency
Liabilities / assets9.5%
Debt / equity0.00x
Current ratio8.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35.51M | $32.01M | $27.63M | $32.12M | $27.25M | $23.24M | $17.64M | $20.44M |
| Cost of revenue | $15.17M | $13.11M | $11.19M | $13.18M | $12.13M | $10.73M | $8.67M | $8.75M |
| Gross profit | $20.33M | $18.90M | $16.44M | $18.94M | $15.12M | $12.50M | $8.97M | $11.69M |
| R&D expense | $11.97M | $10.24M | $10.36M | $10.13M | $8.20M | $8.87M | $7.59M | $9.21M |
| SG&A expense | $9.84M | $9.60M | $9.62M | $8.60M | $7.92M | $7.88M | $6.62M | $4.71M |
| Operating income | -$26.61M | -$25.58M | -$24.27M | -$16.12M | -$17.04M | -$19.87M | -$18.64M | -$13.04M |
| Net income | -$24.35M | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -$28.66M | -$18.11M |
| EBITDA | -$25.72M | -$24.87M | -$23.69M | -$15.59M | -$16.66M | -$19.52M | -$18.34M | -$12.80M |
| EPS (basic) | -0.52 | -0.53 | -0.49 | — | -0.33 | -0.39 | -0.93 | — |
| EPS (diluted) | -0.52 | -0.53 | -0.49 | — | -0.33 | -0.39 | -0.93 | — |
| Weighted avg. shares (diluted) | 46.54M | 44.55M | 44.44M | — | 43.63M | 43.39M | 30.71M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $81.55M | $44.32M | $30.21M | $31.58M | $38.48M | $35.08M | $42.45M | $30.53M |
| Short-term investments | $158.65M | $136.17M | $169.31M | $187.55M | $190.20M | $214.65M | $189.02M | $73.14M |
| Receivables | $20.67M | $18.05M | $15.75M | $17.12M | $11.54M | $11.39M | $9.06M | $12.00M |
| Inventory | $22.97M | $23.92M | $23.73M | $21.72M | $20.37M | $17.32M | $15.73M | $13.32M |
| Current assets | $292.95M | $231.03M | $247.99M | $267.90M | $270.03M | $286.07M | $261.92M | $132.92M |
| PP&E, net | $11.76M | $10.75M | $10.16M | $8.60M | $7.38M | $6.46M | $5.51M | $4.78M |
| Total assets | $443.76M | $292.39M | $304.42M | $328.74M | $330.05M | $329.97M | $338.02M | $149.65M |
| Current liabilities | $32.84M | $26.02M | $23.19M | $30.92M | $25.39M | $19.49M | $16.49M | $21.15M |
| Total liabilities | $42.38M | $36.02M | $33.17M | $41.13M | $35.29M | $28.34M | $24.27M | $73.63M |
| Shareholders' equity | $401.38M | $256.37M | $271.25M | $287.61M | $294.76M | $301.63M | $313.75M | -$245.36M |
| Shares outstanding | 54.36M | 44.98M | 44.56M | 44.36M | 43.99M | 43.47M | 43.35M | 6.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.29M | -$14.62M | -$23.83M | -$8.63M | -$8.73M | -$13.59M | -$19.98M | -$14.28M |
| Capital expenditure | $2.27M | $1.04M | $1.38M | $1.90M | $1.28M | $1.78M | $333,000 | $561,000 |
| Free cash flow | -$14.56M | -$15.66M | -$25.21M | -$10.53M | -$10.01M | -$15.37M | -$20.31M | -$14.84M |
| Investing cash flow | -$114.08M | $26.93M | $21.84M | $658,000 | $9.49M | $6.17M | -$179.12M | -$29.66M |
| Financing cash flow | $163.60M | $1.80M | $623,000 | $1.06M | $2.65M | $42,000 | $211.12M | $56.89M |
| Depreciation & amortization | $892,000 | $709,000 | $585,000 | $538,000 | $385,000 | $347,000 | $303,000 | $232,000 |
| Stock-based compensation | $6.71M | $7.02M | $5.41M | $4.30M | $4.48M | $4.80M | $2.80M | $1.55M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.